1. Home
  2. CTSH vs VTRS Comparison

CTSH vs VTRS Comparison

Compare CTSH & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cognizant Technology Solutions Corporation

CTSH

Cognizant Technology Solutions Corporation

N/A

Current Price

$58.90

Market Cap

22.3B

Sector

Technology

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

N/A

Current Price

$16.21

Market Cap

18.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTSH
VTRS
Founded
1994
1961
Country
United States
United States
Employees
N/A
30000
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3B
18.7B
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
CTSH
VTRS
Price
$58.90
$16.21
Analyst Decision
Buy
Buy
Analyst Count
17
4
Target Price
$80.47
$13.50
AVG Volume (30 Days)
8.9M
10.3M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
2.41%
3.21%
EPS Growth
1.11
N/A
EPS
1.39
0.05
Revenue
$21,108,000,000.00
$14,299,900,000.00
Revenue This Year
$8.17
$4.41
Revenue Next Year
$5.06
$1.96
P/E Ratio
$42.66
$320.90
Revenue Growth
6.95
N/A
52 Week Low
$37.08
$9.43
52 Week High
$87.03
$18.39

Technical Indicators

Market Signals
Indicator
CTSH
VTRS
Relative Strength Index (RSI) 73.57 40.73
Support Level $58.75 $15.82
Resistance Level $62.66 $16.54
Average True Range (ATR) 2.74 0.52
MACD 0.52 -0.20
Stochastic Oscillator 92.25 12.95

Price Performance

Historical Comparison
CTSH
VTRS

About CTSH Cognizant Technology Solutions Corporation

Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services. Originally founded in India, the company is headquartered in the US and serves enterprise customers spanning the financial services, healthcare, and resources industries. With most of its workforce located in India, Cognizant leverages a global delivery model that helps clients outsource their IT needs to offshore labor.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: